|
End-of-day quote
Shanghai S.E.
26/10/2026
|
5-day change | 1st Jan Change | ||
| 19.00 CNY | +4.63% |
|
-0.37% | +7.83% |
| 10-23 | DaShenLin Pharmaceutical Completes Maturity Redemption of Convertible Bonds | MT |
| 10-14 | Dashenlin Pharmaceutical to Redeem Dashen Convertible Bonds | MT |
Business description: DaShenLin Pharmaceutical Group Co., Ltd.
Number of employees: 41,141
Sales by Activity: DaShenLin Pharmaceutical Group Co., Ltd.
| Fiscal Period: December | 2021 (CNY) | 2022 (CNY) | 2023 (CNY) | 2024 (CNY) | 2025 (CNY) |
|---|---|---|---|---|---|
Retail | 15.28B | 19.24B | 20.49B | 21.91B | 22.35B |
Franchise and Distribution | 1.01B | 1.54B | 3.42B | 3.94B | 4.48B |
Other Operations | 447M | 444M | 589M | 617M | 635M |
Geographical breakdown of sales: DaShenLin Pharmaceutical Group Co., Ltd.
| Fiscal Period: December | 2021 (CNY) | 2022 (CNY) | 2023 (CNY) | 2024 (CNY) | 2025 (CNY) |
|---|---|---|---|---|---|
China | 16.76B | 21.25B | 24.53B | 26.5B | 27.5B |
Executive Committee: DaShenLin Pharmaceutical Group Co., Ltd.
| Manager | Title | Age | Since |
|---|---|---|---|
Guo Qiang Ke
CEO | Chief Executive Officer | 44 | 28/02/2019 |
Guang Zhi Peng
DFI | Director of Finance/CFO | 44 | 10/05/2018 |
Zhi Hui Chen
HRO | Human Resources Officer | 48 | - |
Qun Fei Tan
PRN | Corporate Officer/Principal | 59 | 30/05/2015 |
Wen Sheng Chen
PRN | Corporate Officer/Principal | 45 | 03/02/2023 |
Composition of the Board of Directors: DaShenLin Pharmaceutical Group Co., Ltd.
| Director | Title | Age | Since |
|---|---|---|---|
Yun Feng Ke
CHM | Chairman | 59 | 16/07/2013 |
Guo Chang Liu
BRD | Director/Board Member | 63 | 08/08/2016 |
Zhi Hui Chen
CHM | Chairman | 48 | 28/05/2015 |
Guo Qiang Ke
BRD | Director/Board Member | 44 | 08/02/2024 |
Jie Li
BRD | Director/Board Member | 60 | 20/11/2019 |
Li Ping Lu
BRD | Director/Board Member | 53 | 20/11/2019 |
Zu Yao Su
BRD | Director/Board Member | 63 | 20/11/2019 |
Wen Sheng Chen
BRD | Director/Board Member | 45 | 03/02/2023 |
Jin Shu Shi
BRD | Director/Board Member | 40 | 03/02/2023 |
Qun Fei Tan
BRD | Director/Board Member | 59 | 08/02/2024 |
Company details: DaShenLin Pharmaceutical Group Co., Ltd.
DaShenLin Pharmaceutical Group Co., Ltd.
410, 410-1, Longxi Avenue
510000, Guangzhou
+86 20 8168 9688
http://www.dslyy.com
Other Drug Retailers
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +4.63% | -0.37% | +1.71% | -17.68% | 3.24B | |
| -1.43% | -6.73% | -41.03% | +3.83% | 15.31B | |
| -22.53% | -26.38% | -18.16% | -38.93% | 5.04B | |
| -1.75% | +0.58% | -9.51% | +0.52% | 6.63B | |
| -1.40% | -1.73% | -16.58% | +3.38% | 6.48B | |
| -1.93% | -8.52% | -53.88% | -39.87% | 5.86B | |
| +0.67% | +0.63% | +1.27% | -3.48% | 4.64B | |
| -1.08% | -3.53% | -13.77% | -16.76% | 3.21B | |
| +2.95% | -7.78% | -40.61% | -14.82% | 3.1B | |
| -0.99% | -3.02% | -27.65% | +28.37% | 2.98B | |
| Average | -2.29% | -3.87% | -21.82% | -9.54% | 5.65B | |
| Weighted average by Cap. | -2.59% | -3.50% | -25.62% | -7.69% |
Sector
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- 603233 Stock
- Company DaShenLin Pharmaceutical Group Co., Ltd.
Select your edition
All financial news and data tailored to specific country editions
